Navigation Links
Oncothyreon highlights corporate and clinical objectives for 2008
Date:1/28/2008

BELLEVUE, WA, Jan. 28 /PRNewswire-FirstCall/ - Oncothyreon Inc. (the "Company") (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today provided a review of the Company's clinical development plans and corporate objectives for 2008. Oncothyreon is developing both novel synthetic vaccines and targeted small molecules with the potential to improve the lives and outcomes of cancer patients.

"During 2008, our primary focus will continue to be the advancement of our clinical pipeline," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "We are committed to the rapid development of our product candidates as the best strategy for building long-term value for our shareholders and achieving our vision of developing important new cancer therapies."

"As we advance our clinical programs, we also remain committed to prudent management of our financial resources," continued Dr. Kirkman. "The manufacturing revenue and milestone payments we anticipate receiving under our collaboration with Merck KGaA of Darmstadt, Germany for Stimuvax(R) are expected to support the further development of this product without material additional investment by Oncothyreon. We believe Stimuvax has substantial upside potential if it is approved and marketed, as our agreements with Merck KGaA include significant commercialization milestones and royalties on Stimuvax sales. With respect to our small molecule programs, we are actively seeking a partner for one or more of our product candidates, in order to provide additional resources for these product candidates, while generating revenue to support ongoing development of other compounds
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Highlights of Economic and Business Growth in the Tampa Bay Region
3. Highlights of Economic and Business Growth in the Tampa Bay Region
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007
6. Highlights of Economic and Business Growth in the Tampa Bay Region
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
9. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
10. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
11. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... Sleepless nights ... an individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound sleepers ... voice command technology makes it effortless to use, while the integration of the Bluetooth ...
(Date:7/1/2015)... , July 1, 2015   Decision Resources ... cited advantages of Otezla are its oral administration, ... as reported by surveyed rheumatologists. Otezla was the ... the treatment of active psoriatic arthritis in ... standard of care includes conventional oral treatments including ...
(Date:7/1/2015)... HAMILTON, Bermuda , July 1, 2015 /PRNewswire/ ... biopharmaceutical company focused on the treatment of dementia, ... investor briefing on July 22 at 5:45 p.m. ... at the Alzheimer,s Association International Conference 2015 (AAIC). ... following remarks: , Dr. Lawrence ...
(Date:7/1/2015)... Indianapolis, IN (PRWEB) , ... July 01, 2015 , ... ... the 2015 BIO International Convention in Philadelphia, PA. , The presentation took ... milestones and outlined the plans for the development of APX3330 for the treatment of ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2
... the Gladstone Institute of Neurological Disease (GIND) have uncovered ... (AD) and other neurodegenerative diseases. The results might lead ... examined a protein called tau that has been strongly ... author on the study. "Tau forms toxic protein aggregations ...
... Maui County officials at that time agreed with ... that someone with their experience in scrap metal ... In March of 2005, the headline of the Maui ... Stepping into this island-wide disaster was SOS Metals ...
... Sept. 22 Signal Genetics, a privately held predictive ... company will work with Array BioPharma to help push ... helping bring personalized medicine and companion diagnostics to patients ... and antibody producing cells. Signal Genetics, groundbreaking ...
Cached Biology Technology:Gladstone scientists identify strategy to reduce toxic proteins associated with Alzheimer's disease 2SOS Metals Island Recycling Sold to Schnitzer Steel Industries 2
(Date:6/24/2015)... 24, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Sharp has selected its industry-leading ... for its latest flagship smartphone device, the AQUOS ... million shipments of its fingerprint ID sensor technology, ... scalability and leadership in the biometrics market through ...
(Date:6/24/2015)... MARTIGNY, Switzerland , June 24, 2015 /PRNewswire/ ... strategic partnership with emerging biometric password solution one ... http://photos.prnewswire.com/prnh/20150623/225014LOGO one face in, ... offers a ground-breaking and affordable multifactor-authentication biometric answer ... speaker recognition technology, provided in partnership with KeyLemon, ...
(Date:6/23/2015)... Research and Markets( ... "Body-Worn Temperature Sensors Market - Global Industry ... - 2020" report to their offering. ... global body-worn temperature sensors market. The global body-worn ... basis of types, care setting, patient demographic, applications ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... is available in German . , ... has developed a model, which identifies potential habitats and corridors ... Rheinland-Pfalz as an example, it was demonstrated that almost half ... enabling a maximum population of 1600 females. The model can ...
... is a link between alcohol consumption and increased risk of ... 5,870 young adult women. The study, published in ... found that the risk increased 3% for every additional alcoholic ... observe any increase in risk of seasonal allergic rhinitis according ...
... Achieves record biometric revenues and profitability, WALL, ... Board: BKYI), a leader in wireless public safety ... profitability and strong revenue growth for its second ... continuing operations for the quarter ended June 30,2008 ...
Cached Biology News:Let the cat keep chasing the mouse 2Let the cat keep chasing the mouse 3Let the cat keep chasing the mouse 4Alcohol is associated with risk of perennial allergic rhinitis 2BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 2BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 3BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 4BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 5
... Morris Water MazeRecords animal movements in a ... subjects at once in a predefined sequence of ... instruments all built around a video camera, frame ... track two fields at once and up to ...
... Place AvoidanceIncludes all features of Tracker, plus ... a user defined subsection of the arena, and ... family of instruments all built around a video ... that can track two fields at once and ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
Biology Products: